Race Oncology Ltd
Company Profile
Business description
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.
Contact
1 Macquarie Place
Level 36, Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
stocks
Is this overpriced ASX share too much of a gamble?
stocks
ASX players that might thrive under a Trump administration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,539.00 | 59.10 | 0.70% |
| CAC 40 | 7,269.63 | 42.17 | -0.58% |
| DAX 40 | 19,210.81 | 52.89 | -0.27% |
| Dow JONES (US) | 43,444.99 | 305.87 | -0.70% |
| FTSE 100 | 8,063.61 | 7.58 | -0.09% |
| HKSE | 19,426.34 | 9.47 | -0.05% |
| NASDAQ | 18,680.12 | 427.53 | -2.24% |
| Nikkei 225 | 38,642.91 | 107.21 | 0.28% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,870.62 | 78.55 | -1.32% |
| S&P/ASX 200 | 8,285.20 | 61.20 | 0.74% |
| SSE Composite Index | 3,330.73 | 49.11 | -1.45% |